Loading…
Employees: 1,490
Size Guangzhou Jet Bio-Filtration (688026.SS) is a China Health Care company (Medical Specialties) with a market value of $471M, the 4006th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥22.37 on 6 Nov 2026.
Performance Over six months the shares gained 40.3%, against -15.0% for the median peer and -16.4% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 4.6% over the last twelve months (peer median -0.6%); the operating margin is 10.7% (peer median 6.3%).
Valuation It trades at 38.6× forward earnings against a peer median of 20.0× (2nd most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.2 points below its cost of capital (8.8% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥591M | CN¥559M | CN¥555M | CN¥461M | CN¥605M |
| Revenue growth | — | +1% | +20% | -24% | — |
| Gross profit | CN¥264M | CN¥213M | CN¥213M | CN¥129M | CN¥179M |
| EBITDA | n/a | CN¥152M | CN¥169M | CN¥99.1M | CN¥148M |
| Net income | CN¥25.0M | CN¥48.2M | CN¥75.6M | CN¥34.8M | CN¥87.7M |
| Free cash flow | CN¥52.6M | CN¥70.7M | -CN¥56.7M | -CN¥48.9M | -CN¥7.00M |
| Capital expenditure | CN¥92.5M | CN¥124M | CN¥111M | CN¥184M | CN¥173M |
| Total debt | CN¥410M | CN¥387M | CN¥363M | CN¥340M | CN¥452M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688026.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.5% | -5.0% | 2nd lowest of 21 |
| 6-month return | +40.3% | -15.0% | 2nd highest of 21 |
| Distance from 52-week high | -26.9% | -37.7% | 4th highest of 21 |
| Revenue growth (TTM) | +4.6% | -0.6% | 7th highest of 21 |
| Operating margin | 10.7% | 6.3% | 10th highest of 21 |
| Forward P/E | 38.6× | 20.0× | 2nd most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 22.1% | 11.7% | 5th most demanding of 13 |
| Growth delivered (Del g) | +2.2% | +6.7% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | +19.9 pp | +6.5 pp | 4th most demanding of 13 |
| ROIC minus cost of capital | -2.2 pp | -2.7 pp | 9th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 38.6× | 22.1% | +2.2% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | n/a | 42.6% | +0.4% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | n/a | 6.7% | +0.3% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | n/a | 22.2% | -11.7% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | n/a | 3.8% | -2.8% |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 12.2× | n/a | n/a |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | 6.7× | n/a | n/a |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | n/a | n/a | n/a |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | n/a | 35.5% | -6.9% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 12.2× | -5.6% | +7.7% |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 23.6× | n/a | n/a |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 14.1× | 0.9% | +15.6% |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | n/a | n/a | n/a |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 12% | 27.4× | 34.3% | +18.8% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | n/a | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 18.5× | 19.3% | +12.4% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 21.6× | 11.8% | +5.6% |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | n/a | n/a | n/a |